CliffBio
small molecule

OPSUMIT

MACITENTAN

Loss of exclusivityOctober 2029latest FDA-listed patent expiry
CompanyActelion →View the full company profile on CliffBio

Drug detail

Brand nameOPSUMIT
Active ingredientMACITENTAN
Strength10MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2013
Marketing statusRX

Listed patents

PatentExpiresType
8268847*PEDOctober 2029—
8268847April 2029use U-1446
8367685*PEDApril 2029—
8367685October 2028product
9265762*PEDNovember 2027—
9265762May 2027product
10946015*PEDMarch 2027—
10946015September 2026product
7094781*PEDJune 2026—
7094781December 2025substance, product

Regulatory exclusivity

CodeExpires
PEDAugust 2028
M-187February 2028

More from Actelion

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OPSUMIT patent cliff — loss of exclusivity October 2029 | CliffBio